매사추세츠의 전이성 암 임상 시험
전이성 암 관련 연구 63개가 매사추세츠 내 여러 지역에서 참여자를 모집하고 있습니다.
매사추세츠의 도시
공식 연구 텍스트(영어)
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
12세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT05372640Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04585958A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07458347Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- 외 1개
피험자 모집 중2상
전 연령 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT05564377Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT05372614A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Massachusetts General Hospital, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07020221A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT05384626A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital (MG), Boston
피험자 모집 중1상
18세 ~ 99세 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT06983743A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
19세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT06586957A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07029399A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Mass General Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- University of Massachusetts Medical School, Worcester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07174336A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06465069A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Massachusetts Chan Medical School, Worcester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07213804A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07114601A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Boston Medical Center, Boston
- Lahey Hospital & Medical Center, Burlington
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06119581FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05614739A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- Massachusetts General Hospital, Boston
피험자 모집 중1/2상
18세 이상 · 여성 · 2026. 11. 3. 업데이트됨 · NCT04802759Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT06943755Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
- Dana-Farber Cancer Institute, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06127407A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Boston
- Research Site, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06835569Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
- Massachusetts General Hospital, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT07364474A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 22. 업데이트됨 · NCT04657068Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 20. 업데이트됨 · NCT06311214A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 20. 업데이트됨 · NCT06521554A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 19. 업데이트됨 · NCT06244771Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 16. 업데이트됨 · NCT07137416AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Boston
피험자 모집 중1/2상
18세 ~ 75세 · 모든 성별 · 2026. 10. 16. 업데이트됨 · NCT07038343Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
- Mass General Cancer Center, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT06915753A Study of ASP3082 in Adults With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT05382559Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Massachusetts General Hospital Cancer Center, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06757634Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT07227415Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
- Dana-Farber Brigham Cancer Center - Foxborough, Foxborough
- 외 2개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT07222800A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Massachusetts General Hospital, Boston
- University of Massachusetts Medical School, Worcester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 7. 업데이트됨 · NCT07218380FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 7. 업데이트됨 · NCT05919264BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- Avenzo Therapeutics Recruiting Site, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT07193511The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04585750Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06625775A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Dana Farber Cancer Institute., Boston
피험자 모집 중1/2상
25세 이하 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT04094610A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Mass General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT05118789Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06302621ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.